Lucinda Buescher, MD

Professor, Department of Internal Medicine, Division Chief, Dermatology
Internal Medicine

    About me

    Academic Interests:  Dermatoimmunology; Melanoma; How environment, nutrition and lifestyle impact skin health.

    Clinical Interests:  Inflammatory skin diseases including acne and psoriasis; Skin manifestations of connective tissue disease and internal malignancy; Skin cancer.

    Gender

    Female

    Education & training

    Positions
    Dermatologist
    Board Certifications
    Dermatology
    Medical School
    University of Missouri, Columbia, MO - 1986
    Undergraduate Degree
    University of Missouri, Columbia, MO - 1982
    Residency
    University of Missouri Hospital & Clinics, Columbia, MO - Dermatology - 1990

    Research

    Research Interests
    Psoriasis, acne

    Publications

    Ade R1, Sukut C, Wiser HJ, Shockman S, Buescher L. Shiitake dermatitis demonstrating Köebner phenomenon.    Int J Dermatol. 2014 Jul 11. doi: 10.1111/ijd.12361. [Epub ahead of print]

    Shockman S, Buescher LS, Stone SP.  Syphilis in the United States.  Clin Dermatol 2014 Mar-Apr;32(2):213-8.

    Kruse L, Buescher L, Nietert E.  Intravascular B-cell lymphoma presenting as retiform purpura.  Journal of the American Academy of Dermatology 2012 Nov;67(5):e238-40.

    DeWitt CA, Buescher L, Stone S. Cutaneous Manifestations of Internal Malignant Disease: Cutaneous Paraneoplastic Syndromes in Fitzpatrick’s Dermatology in General Medicine, 8th edition Goldsmith et al. (eds.) McGraw Hill, 2012:1880-1900.

    Clinical trials

    Trial
    Dermatology

    Corrona Psoriasis (PSO) Registry

    Active recruiting

    The objective of the Corrona Psoriasis Registry is to create a national database of patients with psoriasis. Data collected will be used to study the  disease and to evaluate the effectiveness and safety of medications approved for the treatment of psoriasis.

    Trial
    Dermatology

    A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

    Active not recruiting

    The purpose of this study is to evaluate the long-term safety, tolerability, and effectiveness of PF-06651600(Ritlecitinib) in adult and adolescent (12 years and older) participants with Alopecia Areata.